155 related articles for article (PubMed ID: 7726659)
1. A study of serum CASA and CA 125 levels in patients with ovarian carcinoma.
Meisel M; Straube W; Weise J; Burkhardt B
Arch Gynecol Obstet; 1995; 256(1):9-15. PubMed ID: 7726659
[TBL] [Abstract][Full Text] [Related]
2. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
[TBL] [Abstract][Full Text] [Related]
3. Predictive and prognostic values of cancer-associated serum antigen (CASA) and cancer antigen 125 (CA 125) levels prior to second-look laparotomy for ovarian cancer.
Kierkegaard O; Mogensen O; Mogensen B; Jakobsen A
Gynecol Oncol; 1995 Nov; 59(2):251-4. PubMed ID: 7590482
[TBL] [Abstract][Full Text] [Related]
4. Serum mucin antigens CASA and MSA in tumors of the breast, ovary, lung, pancreas, bladder, colon, and prostate. A blind trial with 420 patients.
Devine PL; McGuckin MA; Ramm LE; Ward BG; Pee D; Long S
Cancer; 1993 Sep; 72(6):2007-15. PubMed ID: 7689923
[TBL] [Abstract][Full Text] [Related]
5. The management of ovarian carcinoma is improved by the use of cancer-associated serum antigen and CA 125 assays.
Ward BG; McGuckin MA; Ramm LE; Coglan M; Sanderson B; Tripcony L; Free KE
Cancer; 1993 Jan; 71(2):430-8. PubMed ID: 8422635
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of two new assays for tumor-associated antigens, CASA and OSA, found in the serum of patients with epithelial ovarian carcinoma--comparison with CA125.
McGuckin MA; Layton GT; Bailey MJ; Hurst T; Khoo SK; Ward BG
Gynecol Oncol; 1990 May; 37(2):165-71. PubMed ID: 1693126
[TBL] [Abstract][Full Text] [Related]
7. Predictive values of serum tumour markers tetranectin, OVX1, CASA and CA125 in patients with a pelvic mass.
Hogdall EV; Høgdall CK; Tingulstad S; Hagen B; Nustad K; Xu FJ; Bast RC; Jacobs IJ
Int J Cancer; 2000 Nov; 89(6):519-23. PubMed ID: 11102897
[TBL] [Abstract][Full Text] [Related]
8. [Serum CA 125 and ferritin in patients with ovarian carcinoma].
Kanajet D; Klarić P; Filjak K
Jugosl Ginekol Perinatol; 1988; 28(5-6):125-8. PubMed ID: 3216687
[No Abstract] [Full Text] [Related]
9. Human kallikrein 6 (hK6): a new potential serum biomarker for diagnosis and prognosis of ovarian carcinoma.
Diamandis EP; Scorilas A; Fracchioli S; Van Gramberen M; De Bruijn H; Henrik A; Soosaipillai A; Grass L; Yousef GM; Stenman UH; Massobrio M; Van Der Zee AG; Vergote I; Katsaros D
J Clin Oncol; 2003 Mar; 21(6):1035-43. PubMed ID: 12637468
[TBL] [Abstract][Full Text] [Related]
10. Is CA-125 monitoring useful in patients with epithelial ovarian carcinoma and preoperative negative CA-125 serum levels?
Sevelda P; Rosen A; Denison U; Barrada M; Spona J; Salzer H
Gynecol Oncol; 1991 Nov; 43(2):154-8. PubMed ID: 1743558
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of CA 125 and CA 72-4 in ovarian borderline tumors.
Lenhard MS; Nehring S; Nagel D; Mayr D; Kirschenhofer A; Hertlein L; Friese K; Stieber P; Burges A
Clin Chem Lab Med; 2009; 47(5):537-42. PubMed ID: 19317653
[TBL] [Abstract][Full Text] [Related]
12. Clinical Value of Serum HE4, CA125, CA72-4, and ROMA Index for Diagnosis of Ovarian Cancer and Prediction of Postoperative Recurrence.
Wang Q; Wu Y; Zhang H; Yang K; Tong Y; Chen L; Zhou Q; Guan S
Clin Lab; 2019 Apr; 65(4):. PubMed ID: 30969083
[TBL] [Abstract][Full Text] [Related]
13. Use of tetranectin, CA-125 and CASA to predict residual tumor and survival at second- and third-look operations for ovarian cancer.
Høgdall CK; Høgdall EV; Hørding U; Toftager-Larsen K; Arends J; Nørgaard-Pedersen B; Clemmensen I
Acta Oncol; 1996; 35(1):63-9. PubMed ID: 8619942
[TBL] [Abstract][Full Text] [Related]
14. The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis.
Gadducci A; Ferdeghini M; Prontera C; Moretti L; Mariani G; Bianchi R; Fioretti P
Gynecol Oncol; 1992 Feb; 44(2):147-54. PubMed ID: 1312052
[TBL] [Abstract][Full Text] [Related]
15. Are CASA and CA125 concentrations in peripheral blood sourced from peritoneal fluid in women with pelvic masses?
Ward BG; McGuckin MA
Cancer; 1994 Mar; 73(6):1699-703. PubMed ID: 8156497
[TBL] [Abstract][Full Text] [Related]
16. [Usefulness of determining tumor markers CEA, CA125 and CA72-4 in blood serum of patients with ovarian carcinoma].
Kokocińska D; Worwag J; Tomala J; Dzieciuchowicz L; Nowak S; Kuśmierski S
Ginekol Pol; 1994 Sep; 65(9):495-501. PubMed ID: 7721162
[TBL] [Abstract][Full Text] [Related]
17. Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125).
Gronlund B; Høgdall EV; Christensen IJ; Johansen JS; Nørgaard-Pedersen B; Engelholm SA; Høgdall C
Int J Biol Markers; 2006; 21(3):141-8. PubMed ID: 17013795
[TBL] [Abstract][Full Text] [Related]
18. Usefulness of determination of CA-125 in monitoring patients with ovarian carcinoma.
Kamińska JA; Kowalska MM; Sablińska B; Pietrzak P
Eur J Gynaecol Oncol; 1993; 14 Suppl():128-32. PubMed ID: 8200363
[TBL] [Abstract][Full Text] [Related]
19. Prostasin, a potential serum marker for ovarian cancer: identification through microarray technology.
Mok SC; Chao J; Skates S; Wong K; Yiu GK; Muto MG; Berkowitz RS; Cramer DW
J Natl Cancer Inst; 2001 Oct; 93(19):1458-64. PubMed ID: 11584061
[TBL] [Abstract][Full Text] [Related]
20. Serum copper in ovarian carcinoma.
Jacobs AJ; Sommers GM; Axelrod JH; Galakatos AE; Kao MS; Camel HM
Cancer; 1988 Mar; 61(5):1015-7. PubMed ID: 3422179
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]